This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe
Save the date!
November 6–8, 2023Munich, Germany

Oxurion - ONSITE PRESENTER

Profile

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. 

Oxurion aims to play an important role in the treatment of retinal disorders, including the successful clinical development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy.  The company expects the Phase 2b results within <12 months.

Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. 

We're bringing you

  • Company Presentations

    11:05